Home > Press > Press releases

Press releases

Photos

Videos

Documents

NYSE Euronext welcomes Novagali on its European market - 2010/07/22

Novagali Pharma, a pharmaceutical company that develops innovative ophthalmic products, today announces its IPO on NYSE Euronext Paris and the raising of €21,993,750 from investors. Given the recent deterioration in the financial markets, the share price applicable to the Global Placement (...)

[+] Read more

NYSE Euronext welcomes Novagali on its European market - 2010/07/22

Novagali Pharma, a pharmaceutical company that develops innovative ophthalmic products, today announces its IPO on NYSE Euronext Paris and the raising of €21,993,750 from investors.

Given the recent deterioration in the financial markets, the share price applicable to the Global Placement and the Open Price Offering was set at 3.40 euros per share, below the indicative IPO price bracket initially proposed (5.80 to 6.80 euros).

Biosystems  International raises  2,1 M€ - 2010/07/19

Biosystems  International  (BSI) SAS,  biotech leader in the development of monoclonal antibody based diagnostics for cancer, annouced today that it has closed a round of funding amounting to €2,1 million ($2,7 million).

Collaboration between Cancer Campus & Genopole - 2010/06/30

Genopole® (Evry) & Cancer Campus® (Villejuif) June 30, 2010 formalize their collaboration to improve the number and overall development prospects of young innovative companies .

Press release in french

Introduction en bourse de Novagali sur NYSE Euronext Paris - 2010/06/29

A la suite de l’enregistrement par l’Autorité des marchés financiers (AMF) de son document de base, sous le numéro I.10-049 en date du 23 juin 2010, Novagali Pharma, société pharmaceutique développant des produits ophtalmiques innovants, annonce aujourd’hui que l’AMF a apposé le 28 juin 2010 le visa numéro 10-209 sur le prospectus relatif à son introduction en bourse sur NYSE Euronext Paris. L’Offre et l’admission des actions de la Société aux négociations sur NYSE Euronext Paris sont destinées à fournir à la Société des moyens supplémentaires pour accélérer et intensifier le développement de ses quatre produits prioritaires : Cyclokat® (phase III), Vekacia® (Phase III), Catioprost® (Phase II) et Cortiject® (Phase I).

Centaure Metrix  ans Astelia - Prevention of senior - 2010/06/04

Press release in french

Astelia  et  Centaure  Métrix,  deux  sociétés  innovantes  dans  le  domaine  de  la santé  se  sont  alliées  pour  développer  une  solution  pour  la  prévention  des  chutes  des  personnes  âgées.

Nutrivercell completes fund raising - 2010/06/14

Press release in french

Nutrivercell®, entreprise de biotechnologie incubée par Genopole, annonce avoir reçu plus de 500 K€ de la part des réseaux XMP-Business Angels, Paris Business Angels, CapInitial, Trianon Angels, Angels Santé et Harvard Business School Club de France.

Pages : next page - All pages

[+] Previous page